• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

News

SEGHI Study: Defining the Best Surveillance Strategy in Hodgkin Lymphoma after First-Line Treatment

2 de June de 2021
Cancers (Basel). 2021 May 17;13(10):2412. doi: 10.3390/cancers13102412.ABSTRACTThe…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-06-02 10:00:002021-06-02 10:00:00SEGHI Study: Defining the Best Surveillance Strategy in Hodgkin Lymphoma after First-Line Treatment

Evolution of kinase polypharmacology across HSP90 drug discovery

2 de June de 2021
Cell Chem Biol. 2021 Oct 21;28(10):1433-1445.e3. doi: 10.1016/j.chembiol.2021.05.004.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-06-02 10:00:002021-06-02 10:00:00Evolution of kinase polypharmacology across HSP90 drug discovery

Predicting MHC I restricted T cell epitopes in mice with NAP-CNB, a novel online tool

25 de May de 2021
Sci Rep. 2021 May 24;11(1):10780. doi: 10.1038/s41598-021-89927-5.ABSTRACTLack…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2021-05-25 10:00:002021-05-25 10:00:00Predicting MHC I restricted T cell epitopes in mice with NAP-CNB, a novel online tool

Mammary epithelial cells have lineage-rooted metabolic identities

25 de May de 2021
Nat Metab. 2021 May;3(5):665-681. doi: 10.1038/s42255-021-00388-6.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-05-25 10:00:002021-05-25 10:00:00Mammary epithelial cells have lineage-rooted metabolic identities

Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

15 de May de 2021
Nat Commun. 2021 May 14;12(1):2986. doi: 10.1038/s41467-021-23162-4.ABSTRACTA…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-05-15 10:00:002021-05-15 10:00:00Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studies

14 de May de 2021
Dis Model Mech. 2021 Jul 1;14(7):dmm048223. doi: 10.1242/dmm.048223.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-05-14 10:00:002021-05-14 10:00:00Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studies

Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studies

14 de May de 2021
Dis Model Mech. 2021 Jul 1;14(7):dmm048223. doi: 10.1242/dmm.048223.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-05-14 10:00:002021-05-14 10:00:00Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studies

Long-term results of sirolimus treatment in lymphangioleiomyomatosis: a single referral centre experience

14 de May de 2021
Sci Rep. 2021 May 13;11(1):10171. doi: 10.1038/s41598-021-89562-0.ABSTRACTThere…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-05-14 10:00:002021-05-14 10:00:00Long-term results of sirolimus treatment in lymphangioleiomyomatosis: a single referral centre experience

Glutaminolysis-induced mTORC1 activation drives non-alcoholic steatohepatitis progression

7 de May de 2021
J Hepatol. 2021 May 4:S0168-8278(21)00302-0. doi: 10.1016/j.jhep.2021.04.037.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-05-07 10:00:002021-05-07 10:00:00Glutaminolysis-induced mTORC1 activation drives non-alcoholic steatohepatitis progression

Dose intensity and treatment duration of bortezomib in transplant-ineligible newly diagnosed multiple myeloma

2 de May de 2021
Eur J Haematol. 2021 Aug;107(2):246-254. doi: 10.1111/ejh.13643.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-05-02 10:00:002021-05-02 10:00:00Dose intensity and treatment duration of bortezomib in transplant-ineligible newly diagnosed multiple myeloma

Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study

1 de May de 2021
Eur J Cancer. 2021 Jun;150:190-202. doi: 10.1016/j.ejca.2021.03.035.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-05-01 10:00:002021-05-01 10:00:00Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study

Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma

1 de May de 2021
Cancer Med. 2021 May;10(10):3214-3223. doi: 10.1002/cam4.3881.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-05-01 10:00:002021-05-01 10:00:00Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma
Page 39 of 87«‹3738394041›»

Filter by categories

  • Alemany’s & Piulats’s lab (133)
  • Antolin's lab (36)
  • Aytes's Lab (25)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (110)
  • Sin categoría (5)
  • Sureda's & Farre's Lab (312)
  • Viñals's lab (111)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}